Fulcrum Therapeutics to Participate at the Cantor Virtual Muscular Dystrophy Symposium

Rhea-AI Summary

Fulcrum Therapeutics, Inc. (NASDAQ: FULC) to participate in a fireside chat at the Cantor Virtual Muscular Dystrophy Symposium on April 2, 2024. The Company focuses on developing small molecules for rare genetic diseases.

CAMBRIDGE, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.^® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that management will participate in a fireside chat at the Cantor Virtual Muscular Dystrophy Symposium, being held on Tuesday, April 2, 2024 at 10:40 a.m. ET.

The webcast of the presentation will be accessible here and by visiting the "Events and Presentations" section of Fulcrum Therapeutics’ website at https://ir.fulcrumtx.com/events-and-presentations. A replay of the webcast will be available on Fulcrum Therapeutics’ website for at least 30 days following the presentation.

About Fulcrum Therapeutics
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s two lead programs in clinical development are losmapimod, a small molecule in development for the treatment of facioscapulohumeral muscular dystrophy (FSHD), and pociredir, a small molecule designed to increase expression of fetal hemoglobin and in development for the treatment of sickle cell disease (SCD). Fulcrum uses proprietary technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. For more information, visit www.fulcrumtx.com and follow us on Twitter/X (@FulcrumTx) and LinkedIn.

Contact:
Chris Calabrese
LifeSci Advisors, LLC
ccalabrese@lifesciadvisors.com
917-680-5608

FAQ

When will Fulcrum Therapeutics participate in the fireside chat at the Cantor Virtual Muscular Dystrophy Symposium?

Fulcrum Therapeutics will participate in the fireside chat on Tuesday, April 2, 2024, at 10:40 a.m. ET.

What is the focus of Fulcrum Therapeutics as a company?

Fulcrum Therapeutics focuses on developing small molecules to improve the lives of patients with genetically defined rare diseases.

Where can the webcast of the presentation be accessed?

The webcast of the presentation can be accessed on Fulcrum Therapeutics' website at https://ir.fulcrumtx.com/events-and-presentations.

How long will the replay of the webcast be available?

The replay of the webcast will be available on Fulcrum Therapeutics' website for at least 30 days following the presentation.